Tokyo Tape
Sign in
← Falco Holdings

Half-year report · Q2

4671.TEDINET S100UP43
Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥21.4bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥43.0bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥21.3bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥974m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥851m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥1.0bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥2.3bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥931m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥1.2bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥1.1bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥794m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.7bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥629m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥794m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥629m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥36.2bnat 2024-09-30Cons.Assets
Total assets¥36.4bnat 2024-03-31Cons.Assets
Total assets¥36.7bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥10.2bnat 2024-09-30Cons.Liabilities
Total liabilities¥10.4bnat 2024-03-31Cons.Liabilities
Net assets / equity¥25.9bnat 2024-09-30Cons.Net assets
Net assets / equity¥26.0bnat 2024-03-31Cons.Net assets
Net assets / equity¥26.0bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥10.6bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥10.1bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥10.6bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.1bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥9.2bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥12.6bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥3.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥73m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥860m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥4.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥74.462024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.722023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥56.292023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥74.252024-04-01 → 2024-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥150.92023-04-01 → 2024-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥56.142023-04-01 → 2023-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio71.4%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio71.2%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio70.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30¥0
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30¥0
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥176m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥13.1bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥13.1bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥0
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥726m
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥7.7bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥7.7bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥347m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥538m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥538m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥76m
—segment totalrevenue2024-04-01 → 2024-09-30¥21.4bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥21.4bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥0
—segment totalsegment profit2024-04-01 → 2024-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30¥0
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30¥0
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥270m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥0
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥689m
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥385m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥449m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥449m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥46m
—segment totalrevenue2023-04-01 → 2023-09-30¥21.3bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥21.3bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥0
—segment totalsegment profit2023-04-01 → 2023-09-30¥1.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 522
ItemContextValueUnit
Other noiPrior1YTDDuration54000000JPY
Other noiCurrentYTDDuration33000000JPY
Non operating incomePrior1YTDDuration110000000JPY
Non operating incomeCurrentYTDDuration81000000JPY
Interest expenses noePrior1YTDDuration5000000JPY
Interest expenses noeCurrentYTDDuration2000000JPY
Commission fee noePrior1YTDDuration2000000JPY
Commission fee noeCurrentYTDDuration2000000JPY
Foreign exchange losses noePrior1YTDDuration－JPY
Foreign exchange losses noeCurrentYTDDuration4000000JPY
Loss on insurance cancellation noePrior1YTDDuration11000000JPY
Loss on insurance cancellation noeCurrentYTDDuration5000000JPY
Loss on operation of investment noePrior1YTDDuration6000000JPY
Loss on operation of investment noeCurrentYTDDuration3000000JPY
Other noePrior1YTDDuration5000000JPY
Other noeCurrentYTDDuration0JPY
Non operating expensesPrior1YTDDuration30000000JPY
Non operating expensesCurrentYTDDuration19000000JPY
Ordinary incomePrior1YTDDuration931000000JPY
Ordinary incomeCurrentYTDDuration1036000000JPY
Gain on sales of investment securities eiPrior1YTDDuration68000000JPY
Gain on sales of investment securities eiCurrentYTDDuration196000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration1000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration2000000JPY
Gain on reversal of asset retirement obligations eiPrior1YTDDuration68000000JPY
Gain on reversal of asset retirement obligations eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration138000000JPY
Extraordinary incomeCurrentYTDDuration199000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration11000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration5000000JPY
Impairment loss elPrior1YTDDuration0JPY
Impairment loss elCurrentYTDDuration2000000JPY
Office transfer expenses elPrior1YTDDuration7000000JPY
Office transfer expenses elCurrentYTDDuration－JPY
Extraordinary lossPrior1YTDDuration18000000JPY
Extraordinary lossCurrentYTDDuration8000000JPY
Income before income taxesPrior1YTDDuration1050000000JPY
Income before income taxesCurrentYTDDuration1226000000JPY
Income taxes currentPrior1YTDDuration412000000JPY
Income taxes currentCurrentYTDDuration416000000JPY
Income taxes deferredPrior1YTDDuration8000000JPY
Income taxes deferredCurrentYTDDuration15000000JPY
Income taxesPrior1YTDDuration420000000JPY
Income taxesCurrentYTDDuration432000000JPY
Profit lossPrior1YTDDuration629000000JPY
Profit lossCurrentYTDDuration794000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration629000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration794000000JPY
Profit lossPrior1YTDDuration629000000JPY
Profit lossCurrentYTDDuration794000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass